MA27799A1 - DERIVES DE L'AZAINDOLE COMME INHIBITEURS DU FACTEUR Xa - Google Patents
DERIVES DE L'AZAINDOLE COMME INHIBITEURS DU FACTEUR XaInfo
- Publication number
- MA27799A1 MA27799A1 MA28588A MA28588A MA27799A1 MA 27799 A1 MA27799 A1 MA 27799A1 MA 28588 A MA28588 A MA 28588A MA 28588 A MA28588 A MA 28588A MA 27799 A1 MA27799 A1 MA 27799A1
- Authority
- MA
- Morocco
- Prior art keywords
- factor
- compounds
- factor viia
- disorders
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne des composés représentés par la formule (I) dans laquelle R0, R1, R2, R3, Q, V, G et M ont la signification donnée dans les revendications. Lesdits composés sont des composés pharmacologiquement actifs, ils présentent un fort effet antithrombotique et peuvent par exemple servir à la thérapie et à la prophylaxie de troubles cardiovasculaires tels que des maladies thromboemboliques et des resténoses. Lesdits composés sont par ailleurs des inhibiteurs réversibles du facteur Xa (FXa) et/ou du facteur VIIa (FVIIa) des enzymes de coagulation sanguine, et peuvent être employés dans le cas de troubles caractérisés par une activité indésirable du facteur Xa et/ou du facteur VIIa ou dans le traitement ou la prévention de troubles nécessitant une inhibition du facteur Xa et/ou du facteur VIIa. L'invention concerne par ailleurs des procédés de fabrication des composés représentés par la formule (I), leur utilisation, notamment en tant que principes actifs dans des agents pharmaceutiques, et des préparations pharmaceutiques contenant lesdits composés.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03011304A EP1479680A1 (fr) | 2003-05-19 | 2003-05-19 | Derivés d' azaindole en tant qu'inhibiteurs du facteur Xa |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27799A1 true MA27799A1 (fr) | 2006-03-01 |
Family
ID=33040951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28588A MA27799A1 (fr) | 2003-05-19 | 2005-11-08 | DERIVES DE L'AZAINDOLE COMME INHIBITEURS DU FACTEUR Xa |
Country Status (25)
Country | Link |
---|---|
EP (2) | EP1479680A1 (fr) |
JP (1) | JP4733642B2 (fr) |
KR (1) | KR20060012636A (fr) |
CN (1) | CN100347172C (fr) |
AR (1) | AR045682A1 (fr) |
AU (1) | AU2004238500B2 (fr) |
BR (1) | BRPI0410429A (fr) |
CA (1) | CA2526084A1 (fr) |
CL (1) | CL2004001079A1 (fr) |
CR (1) | CR8088A (fr) |
EC (1) | ECSP056179A (fr) |
HK (1) | HK1089175A1 (fr) |
MA (1) | MA27799A1 (fr) |
MX (1) | MXPA05012156A (fr) |
NO (1) | NO20055911L (fr) |
NZ (1) | NZ543669A (fr) |
OA (1) | OA13169A (fr) |
PE (1) | PE20050554A1 (fr) |
RS (1) | RS20050857A (fr) |
RU (1) | RU2330853C2 (fr) |
TN (1) | TNSN05296A1 (fr) |
TW (1) | TW200510411A (fr) |
UA (1) | UA86767C2 (fr) |
WO (1) | WO2004101563A1 (fr) |
ZA (1) | ZA200508150B (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2629232A1 (fr) * | 2005-11-18 | 2007-05-24 | F. Hoffmann-La Roche Ag | Derives d'azaindole-2-carboxamide |
UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
EP2885301A1 (fr) | 2012-08-17 | 2015-06-24 | Bayer CropScience AG | Amides d'acide azaindole-carboxylique et thiocarboxylique comme insecticides et acaricides |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
CN111834531B (zh) * | 2019-04-15 | 2022-04-19 | 天津大学 | 一种有机半导体材料、制备方法及应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1241472B (it) | 1990-07-06 | 1994-01-17 | Olivier Linda | Dispositivo elettromeccanico per la cattura continua in particolare di topi e ratti. |
US5788965A (en) | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
DE69532754T2 (de) | 1994-04-26 | 2005-03-10 | Aventis Pharmaceuticals, Inc. | Faktor xa inhibitoren |
ATE260103T1 (de) * | 1997-12-19 | 2004-03-15 | Schering Ag | Ortho-anthranilamide derivate als antikoagulantien |
PT1042287E (pt) * | 1997-12-24 | 2005-08-31 | Aventis Pharma Gmbh | Derivados de indole como inibidores do factor xa |
EP0987274A1 (fr) | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Inhibiteurs du facteur VIIa |
JP4241970B2 (ja) * | 1998-10-30 | 2009-03-18 | 中外製薬株式会社 | アミド結合を有するインドール誘導体、及びモノ又はジアザインドール誘導体 |
US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
EP1216228B1 (fr) * | 1999-09-17 | 2008-10-29 | Millennium Pharmaceuticals, Inc. | BENZAMIDES ET INHIBITEURS CORRESPONDANTS DU FACTEUR Xa |
JP2001294572A (ja) * | 2000-02-09 | 2001-10-23 | Dai Ichi Seiyaku Co Ltd | 新規スルホニル誘導体 |
US6436965B1 (en) * | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
WO2002000651A2 (fr) * | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Inhibiteurs du facteur xa |
BR0207952A (pt) * | 2001-03-07 | 2004-07-27 | Pfizer Prod Inc | Moduladores da atividade de receptores de quimiocina |
WO2002080853A2 (fr) * | 2001-04-09 | 2002-10-17 | Bristol-Myers Squibb Company | Inhibiteurs heterocycliques fusionnes du facteur xa |
EP1314733A1 (fr) * | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides comme inhibiteurs du facteur Xa |
WO2003053361A2 (fr) * | 2001-12-20 | 2003-07-03 | Osi Pharmaceuticals, Inc. | COMPOSES D'ANTAGONISTES SELECTIFS DE PYRROLOPYRIMIDINE A2b, LEUR SYNTHESE ET LEUR UTILISATION |
DE10214832A1 (de) * | 2002-04-04 | 2003-10-16 | Merck Patent Gmbh | Phenylderivate 4 |
JP2004203791A (ja) * | 2002-12-25 | 2004-07-22 | Dai Ichi Seiyaku Co Ltd | 芳香族化合物 |
JP2004210716A (ja) * | 2002-12-27 | 2004-07-29 | Dai Ichi Seiyaku Co Ltd | ジアミド誘導体 |
US7135469B2 (en) * | 2003-03-18 | 2006-11-14 | Bristol Myers Squibb, Co. | Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors |
-
2003
- 2003-05-19 EP EP03011304A patent/EP1479680A1/fr not_active Withdrawn
-
2004
- 2004-05-05 KR KR1020057022131A patent/KR20060012636A/ko not_active Application Discontinuation
- 2004-05-05 OA OA1200500323A patent/OA13169A/en unknown
- 2004-05-05 MX MXPA05012156A patent/MXPA05012156A/es active IP Right Grant
- 2004-05-05 BR BRPI0410429-3A patent/BRPI0410429A/pt not_active IP Right Cessation
- 2004-05-05 JP JP2006529743A patent/JP4733642B2/ja not_active Expired - Fee Related
- 2004-05-05 AU AU2004238500A patent/AU2004238500B2/en not_active Expired - Fee Related
- 2004-05-05 RU RU2005139557/04A patent/RU2330853C2/ru not_active IP Right Cessation
- 2004-05-05 EP EP04731161.8A patent/EP1636226B1/fr not_active Expired - Lifetime
- 2004-05-05 CA CA002526084A patent/CA2526084A1/fr not_active Abandoned
- 2004-05-05 RS YUP-2005/0857A patent/RS20050857A/sr unknown
- 2004-05-05 UA UAA200512133A patent/UA86767C2/ru unknown
- 2004-05-05 CN CNB2004800139362A patent/CN100347172C/zh not_active Expired - Fee Related
- 2004-05-05 WO PCT/EP2004/004754 patent/WO2004101563A1/fr active Application Filing
- 2004-05-05 NZ NZ543669A patent/NZ543669A/en unknown
- 2004-05-11 PE PE2004000481A patent/PE20050554A1/es not_active Application Discontinuation
- 2004-05-17 CL CL200401079A patent/CL2004001079A1/es unknown
- 2004-05-17 TW TW093113797A patent/TW200510411A/zh unknown
- 2004-05-17 AR ARP040101694A patent/AR045682A1/es unknown
-
2005
- 2005-10-10 ZA ZA200508150A patent/ZA200508150B/en unknown
- 2005-11-08 MA MA28588A patent/MA27799A1/fr unknown
- 2005-11-11 CR CR8088A patent/CR8088A/es not_active Application Discontinuation
- 2005-11-18 TN TNP2005000296A patent/TNSN05296A1/en unknown
- 2005-11-18 EC EC2005006179A patent/ECSP056179A/es unknown
- 2005-12-13 NO NO20055911A patent/NO20055911L/no not_active Application Discontinuation
-
2006
- 2006-08-30 HK HK06109646A patent/HK1089175A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BRPI0410429A (pt) | 2006-06-06 |
NZ543669A (en) | 2008-12-24 |
EP1636226B1 (fr) | 2014-10-15 |
CN100347172C (zh) | 2007-11-07 |
CN1791601A (zh) | 2006-06-21 |
UA86767C2 (ru) | 2009-05-25 |
NO20055911L (no) | 2006-02-10 |
JP2006528214A (ja) | 2006-12-14 |
JP4733642B2 (ja) | 2011-07-27 |
AU2004238500A1 (en) | 2004-11-25 |
OA13169A (en) | 2006-12-13 |
KR20060012636A (ko) | 2006-02-08 |
MXPA05012156A (es) | 2006-08-18 |
AR045682A1 (es) | 2005-11-09 |
CL2004001079A1 (es) | 2005-04-08 |
PE20050554A1 (es) | 2005-08-04 |
TW200510411A (en) | 2005-03-16 |
HK1089175A1 (en) | 2006-11-24 |
TNSN05296A1 (en) | 2007-07-10 |
ECSP056179A (es) | 2006-08-30 |
EP1636226A1 (fr) | 2006-03-22 |
CA2526084A1 (fr) | 2004-11-25 |
RU2005139557A (ru) | 2007-06-27 |
EP1479680A1 (fr) | 2004-11-24 |
RU2330853C2 (ru) | 2008-08-10 |
AU2004238500B2 (en) | 2010-07-22 |
CR8088A (es) | 2006-09-22 |
RS20050857A (en) | 2007-11-15 |
WO2004101563A1 (fr) | 2004-11-25 |
ZA200508150B (en) | 2007-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27798A1 (fr) | DERIVES DE BENZIMIDAZOLE COMME INHIBITEURS DU FACTEUR Xa | |
TNSN04091A1 (en) | Indole-2-carboxamides as factor xa inhibitors | |
CL2004001074A1 (es) | COMPUESTOS DERIVADOS DE INDOL, 2-AMIDO SUSTITUIDOS, INHIBIDORES DEL FACTO Xa, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION, UTILES PARA PREPARAR UN MEDICAMENTO PARA TRATAR INFARTO DE MIOCARDIO AGUDO, TRASTORNOS CARDIOVASCULARES, APOPLEJIA, | |
ATE429432T1 (de) | Indazolderivate als faktor xa-inhibitoren | |
ATE293617T1 (de) | Oxybenzamidderivate als faktor-xa-inhibitoren | |
MA26697A1 (fr) | Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant | |
MA27146A1 (fr) | INHIBITEURS DU FACTEUR Xa ET D'AUTRES SERINE-PROTEASES IMPLIQUEES DANS LA CASCADE DE LA COAGULATION. | |
TNSN02022A1 (fr) | Triazolopyridines anti-inflammatoires nouvelles, et compositions les contenant | |
TWI222865B (en) | Pharmaceutical composition for treatment of thromboembolic disorder or atherosclerosis or to inhibit blood coagulation | |
IL171843A (en) | TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS | |
MA27799A1 (fr) | DERIVES DE L'AZAINDOLE COMME INHIBITEURS DU FACTEUR Xa | |
KR20070049251A (ko) | 조직 인자 길항제 및 그의 사용 방법 | |
JP2007506720A (ja) | 治療的処置 | |
AR026257A1 (es) | N-guanidinoalquilamidas, su preparacion, su uso y composiciones farmaceuticas que las contienen | |
TW200504027A (en) | Imidazole-derivatives as factor Xa inhibitors | |
TH65773A (th) | อนุพันธ์อินโดลชนิดใหม่ใช้เป็นสารยับยั้ง Xa แฟกเตอร์ | |
JO2467B1 (en) | New indole derivatives as an inhibitor of Xa | |
EP1829535A2 (fr) | Antagonistes de facteur de tissus et leurs procédés d'utilisation | |
TH91551B (th) | การเตรียมและการใช้ของสารประกอบเป็นตัวยับยั้งแอสพาร์ทิล โปรตีเอส | |
CA2076050A1 (fr) | Esters d'alkyliques ramifies d'acides 4-bis(chloroethyl)aminophenylalkylcarboxyliques pour le traitement des tumeurs primaires et metastasiques du systeme lymphatique, ainsi que des cancers du sein et des ovaires | |
MA28302A1 (fr) | Derives de sulfonamides pour le traitement de maladies |